Date Presented 04/21/2023

This study identified unique OT needs of older adults with acute myeloid leukemia (AML) receiving oral venetoclax and infusional hypomethalating agent (VEN + HMA) therapy. A battery of tests performed on 19 older adults in the early stages of chemotherapy suggest that grip strength and mobility decline and the need for more nuanced evaluation of cognition. We found careful evaluation was important to understand cognitive and physical impairments in the context of meaningful occupational challenges.

Primary Author and Speaker: Farrell Leigh Wiggins

Additional Authors and Speakers: Alexis Petteway

Contributing Authors: Mackenzi Pergolotti, Todd Schwartz, Zachary Ripberger, Susan Coppola, Ashley Bryant, Ya-Ning Chan

You do not currently have access to this content.